Alacra Pulse Banner
 

George Hill, Leerink Swann & Company

Search Street Pulse:
 
 
Follow Alacra Pulse on Twitter
Latest Analyst Comments by George Hill, Leerink Swann & Company
 

Acquisition Means More Business For Pharmacy Benefits Manager (Investor''s Business Daily - Business) - Jan 29, 2010

In 2006, it attempted a $26 billion hostile takeover of Caremark Rx, losing to CVS Integration of an acquisition always has risks, says George Hill, an analyst with Leerink Swann 
Recent Research on CVS Caremark Corp (CVS)
CVS/Caremark Corp. (Moody's Global Credit Research)- Nov 25, 2009
Moody's changes CVS Caremark's ratings outlook to stable (Moody's Global Credit Research)- Nov 24, 2009
more research
Share:  In 2006, it attempted a $26 billion hostile takeover of Caremark Rx, losing to <span class="company">CVS</span> Integration of an acquisition always has risks, says <span class="analyst">George Hill</span>, an analyst with Leerink Swann Tweet this 

Obama Stimulus Money Smiles On Medical Technology Company (Investor''s Business Daily - Business) - Dec 02, 2009

They're cheering for the government's stimulus package at Cerner ( CERN ). The $19 billion in federal stimulus funds to motivate hospitals and doctors to convert to electronic medical record keeping means more business for the developer and vendor of health care data keeping software and systems. In fact, the $19 billion is really worth a potential $36 billion when savings resulting from electronic records are taken into account, says George Hill, an analyst with Leerink Swann. "The initial view of our market and our clients and potential new clients is that the stimulus dollars are for real," said Marc Naughton, Cerner chief financial officer. 
Recent Research on Cerner Corporation (CERN)
Cerner Corporation at JPMorgan Healthcare Conference (Thomson Street Events)- Jan 12, 2010
Q3 2009 Cerner Corporation Earnings Conference Call (Thomson Street Events)- Oct 28, 2009
more research
Share:  In fact, the $19 billion is really worth a potential $36 billion when savings resulting from electronic records are taken into account, says <span class="analyst">George Hill</span>, an analyst with Leerink Swann. Tweet this 

After Massive Sell-Off, CVS Gets On-Message (Investor''s Business Daily - Business) - Nov 13, 2009

The high profiles and public interest auras of the departed customers undermine CVS' credibility, says Leerink Swann analyst George Hill.  
Share:  The high profiles and public interest auras of the departed customers undermine <span class="company">CVS</span>' credibility, says Leerink Swann analyst <span class="analyst">George Hill</span>. Tweet this 

Medical Services Company Gets Booster Shot From Swine Flu Vaccine (Investor''s Business Daily - Business) - Nov 03, 2009

An ill wind is blowing some good McKesson 's ( MCK ) way. First, San Francisco based McKesson, the largest health care services company in the U.S., has the contract to distribute swine flu vaccine. Add to that the government incentive for development of health care electronic records, and the company is in good shape to outrun some 2008 setbacks. Whatever shape the final health care legislation takes, it's likely to be good news for McKesson. By giving more people coverage, especially for prescription drugs, it will increase demand for McKesson's services, says George Hill, an analyst with Leerink Swann.  
Recent Research on McKesson Corporation (MCK)
McKesson Corporation (Moody's Global Credit Research)- Feb 12, 2010
McKesson Corporation at JPMorgan Healthcare Conference (Thomson Street Events)- Jan 11, 2010
more research
Share:  By giving more people coverage, especially for prescription drugs, it will increase demand for <span class="company">McKesson</span>'s services, says <span class="analyst">George Hill</span>, an analyst with Leerink Swann. Tweet this 

Andrew Dillon UK&apos;s Head of NICE, Eric Heiden Olympian/Orthopedic Surgeon and McCain/Obama Health Policy Advisors Will Be Featured Speakers Today at AdvaMed 2008 (StreetInsider.com News Articles) - Sep 23, 2008

2:00-3:30 p.m. Moderator: Karen Katz, Director, Health Care & MedTech, Mintz Levin Panelists: Charlie Huiner, Vice President, Business Development, InTouch Health George Hill, Vice President, Investment Banking, Leerink Swann Clint McClellan, Senior Director, Market Development, QUALCOMM Health and Life Sciences Joe Miles, Senior Director, Life Sciences Industry Solution Group, SAP America, Inc. 21st Century Health Policy: The Longevity Boom: Opportunities for Medical Technology Innovation .  
Recent Research on Health Management Associates, Inc. (HMA)
Summary: Health Management Associates Inc. (S&P Credit Research)- Dec 22, 2009
Health Management Associates Inc. (S&P Credit Research)- Dec 22, 2009
more research
Share:  2:00-3:30 p.m. Moderator: Karen Katz, Director, <span class="company">Health</span> Care & MedTech, Mintz Levin Panelists: Charlie Huiner, Vice President, Business Development, InTouch <span class="company">Health</span> <span class="analyst">George Hill</span>, Vice President, Investment Banking, Leerink Swann Clint McClellan, Senior Director, Market Development, QUALCOMM <span class="company">Health</span> and Life Sciences Joe Miles, Senior Director, Life Sciences Industry Solution Group, SAP America, Inc. 21st Century <span class="company">Health</span> Policy: The Longevity Boom: Opportunities for Medical Technology Innovation . Tweet this 

Bio
 

George Hill

Leerink Swann & Company

Quotability Rating:
Quotability Index: the stars indicate how frequently this analyst is quoted in the Street Pulse sources. Five stars represent the top quintile, four stars the next and so forth.
This is me
George Hill

About George Hill:

William Tanner is Head of the Biotechnology Equity Research group at Leerink Swann. Dr. Tanner, who joined the firm in 2002, was previously with SG Cowen Securities Corp., where he served as Managing Director and Biotechnology Analyst. Before joining SG Cowen, he served as Biotechnology Analyst at the former Vector Securities International and at Principal Financial Securities. Prior to his positions in equity research, Dr. Tanner was a Research Associate at Washington University School of Medicine's Center for Immunology and Department of Pathology. Dr. Tanner received his MBA from the Olin School of Business at Washington University and his Ph.D. in Physiology from Texas A&M University. Dr. Tanner did his post-doctorate work at Monsanto Co. in the department of Molecular Genetics and Mammalian Biology. He was a recipient of the National Research Service Award from the National Institutes of Health and received a postdoctoral fellowship at the Juvenile Diabetes Foundation.

Analyst Comment Ticker
 
Key:
  • Sell-side Sell-side
  • Blog Blog
  • Credit Analyst Credit
  • Industry Analyst Industry

Copyright © 2010 Alacra, Inc., 100 Broadway, Suite 1100, New York, NY 10005. All rights reserved.

Reproduction in whole or in part in any form or medium without express written permission is prohibited.